C12N 2501/825
Serotonine
Official title: Serotonine (5-HT); Melatonine
C12N2501/825 (Serotonine) appears on 17 US grants and 23 published applications in this corpus.
Search patents in C12N- Granted patents
- 17
- Published applications
- 23
- Assignees
- 14
- Inventors
- 27
- Latest grant
- 29 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 2 |
| 2013 | 0 | 2 |
| 2014 | 2 | 1 |
| 2015 | 0 | 1 |
| 2016 | 2 | 1 |
| 2017 | 0 | 2 |
| 2018 | 1 | 1 |
| 2019 | 3 | 1 |
| 2020 | 1 | 1 |
| 2021 | 1 | 2 |
| 2022 | 0 | 0 |
| 2023 | 1 | 2 |
| 2024 | 2 | 1 |
| 2025 | 1 | 1 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cancer-killing cells29 Jul 2025US 12,370,216 B2LIfT BioSciences Ltd
- Cancer-killing cells27 Aug 2024US 12,070,473 B2LIfT BioSciences Ltd
- Cancer-killing cells23 Jan 2024US 11,878,033 B2LIfT BioSciences Ltd
- Cancer-killing cells9 May 2023US 11,642,373 B2LIfT BioSciences Ltd
- Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells13 Jul 2021US 11,060,063 B2The Trustees of Columbia University in the City of New York
- Cancer-killing cells23 Jul 2026US 2026/0207663 A2LIfT BioSciences Ltd
- Methods and pharmacological agents for increasing expansion, engraftment or immune output of human hematopoietic stem cells in transplantation and disease settings7 May 2026US 2026/0125645 A1Valorisation Hsj, Limited Partnership
- Cancer-killing cells23 Oct 2025US 2025/0325584 A1LIfT BioSciences Ltd
- Cancer-killing cells20 Jun 2024US 2024/0197776 A1
- Cancer-killing cells2 Nov 2023US 2023/0346834 A1LIfT BioSciences Ltd
Most cited
By later US patents
- Chemically defined medium for human mesenchymal stem cells174US 5,908,782 AOsiris Therapeutics, Inc. · 1999
- Small molecules supporting pluripotent cell growth and methods thereof38US 8,685,726 B2ViaCyte, Inc. · 2014
- Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells16US 10,487,314 B2The Trustees of Columbia University in the City of New York · 2019
- Enamel products and methods of use15US 10,350,147 B2The Research Foundation for The State University of New York · 2019
- Method for neural stem cell differentiation using 5HT-1A agonists12US 7,132,287 B2Psychiatric Genomics, Inc. · 2006